Garrett | Oxford Protein Informatics Group

Predicting the possible shapes a small molecule can adopt is essential to understanding its chemistry and the possible biological roles of candidate drugs. Thus, conformer generation, the process of converting a topological description of a molecule into a set of 3D positions of its constituent atoms, is an essential component of computational drug discovery.

A former member of OPIG, Dr Jean-Paul Ebejer, myself, and Prof. Charlotte Deane, compared the ability of freely-available conformer generation methods:

“(i) to identify which tools most accurately reproduce experimentally determined structures;
(ii) to examine the diversity of the generated conformational set; and
(iii) to benchmark the computational time expended.”

in Ebejer et al., 2012. JP assembled a set of 708 crystal structures of drug-like molecules from the OMEGA validation set and the Astex Diverse Set with which to test the various methods. We found that RDKit, combining its Distance Geometry (DG) algorithm with energy minimization using the MMFF94 force field proved to be a “valid free alternative to commercial, proprietary software”, and was able to generate “a diverse and representative set of conformers which also contains a close conformer to the known structure”.

Following on from our work at InhibOx, and building on the same benchmark set JP assembled, Greg Landrum and Sereina Riniker recently described (Riniker & Landrum, 2015) two new conformer generation methods, ETDG and ETKDG, that improve upon the classical distance geometry (DG) algorithm. They do this by combining DG with knowledge of preferred torsional angles derived from experimentally determined crystal structures (ETDG), and also by further adding constraints from chemical knowledge, such as ‘aromatic rings are be flat’, or ‘bonds connected to triple bonds are colinear’ (ETKDG). They compared DG, ETDG, ETKDG, and a knowledge-based method, CONFECT, and found:

“ETKDG was found to outperform standard DG and the knowledge-based conformer generator CONFECT in reproducing crystal conformations from both small-molecule crystals (CSD data set) and protein−ligand complexes (PDB data set). With ETKDG, 84% of a set of 1290 small-molecule crystal structures from the CSD could be reproduced within an RMSD of 1.0 Å and 38% within an RMSD of 0.5 Å. The experimental torsional-angle preferences or the K terms alone each performed better than standard DG but were not sufficient to obtain the full performance of ETKDG.

Comparison of ETKDG with the DG conformers optimized using either the Universal Force Field (UFF) or the Merck Molecular Force Field (MMFF) showed different results for the two data sets. While FF-optimized DG performed better on the CSD data set, the two approaches were comparable for the PDB data set.”

They also showed (Fig. 13) that their ETKDG method was faster than DG followed by energy minimization, but not quite as accurate in reproducing the crystal structure.

ETKDG takes 3 times as long as DG. The addition of the K terms, i.e., generating ETKDG embeddings instead of ETDG embeddings, increases runtime by only 10% over ETDG (results not shown). Despite the longer runtime per conformer, ETKDG requires on average one-quarter of the number of conformers to achieve performance similar to DG (Figure S12 and Table S4 in the Supporting Information). This results in a net performance improvement, at least when it comes to reproducing crystal conformers.

As measured by performance in reproducing experimental crystal structures, ETKDG is a viable alternative to plain DG followed by a UFF-optimization, so it is of interest how their runtimes compare. Figure 13 (right) plots the runtime for ETKDG versus the runtime for DG + UFF-optimization. The median ratio of the DG + UFF optimization and ETKDG runtimes is 1.97, i.e., DG + UFF optimization takes almost twice as long as ETKDG. Thus, although ETKDG is significantly slower than DG on a per-conformer basis, when higher-quality conformations are required it can provide structures that are the equivalent of those obtained using DG + UFF-optimization in about half the time.

ETKDG looks like a great addition to the RDKit toolbox for conformer generation (and it was great to see JP thanked in the Acknowledgments!).

References

Ebejer, J. P., G. M. Morris and C. M. Deane (2012). “Freely available conformer generation methods: how good are they?” J Chem Inf Model, 52(5): 1146-1158. 10.1021/ci2004658.

Riniker, S. and G. A. Landrum (2015). “Better Informed Distance Geometry: Using What We Know To Improve Conformation Generation.” J Chem Inf Model, 55(12): 2562-2574. 10.1021/acs.jcim.5b00654.

The dominant paradigm in drug discovery has been one of finding small molecules (or more recently, biologics) that bind selectively to one target of therapeutic interest. This reductionist approach conveniently ignores the fact that many drugs do, in fact, bind to multiple targets. Indeed, systems biology is uncovering an unsettling picture for comfortable reductionists: the so-called ‘magic bullet’ of Paul Ehrlich, a single compound that binds to a single target, may be less effective than a compound with multiple targets. This new approach—network pharmacology—offers new ways to improve drug efficacy, to rescue orphan drugs, re-purpose existing drugs, predict targets, and predict side-effects.

Building on work Stuart Armstrong and I did at InhibOx, a spinout from the University of Oxford’s Chemistry Department, and inspired by the work of Shoichet et al. (2007), Álvaro Cortes-Cabrera and I took our ElectroShape method, designed for ultra-fast ligand-based virtual screening (Armstrong et al., 2010 & 2011), and built a new way of exploring the relationships between drug targets (Cortes-Cabrera et al., 2013). Ligand-based virtual screening is predicated on the molecular similarity principle: similar chemical compounds have similar properties (see, e.g., Johnson & Maggiora, 1990). ElectroShape built on the earlier pioneering USR (Ultra-fast Shape Recognition) work of Pedro Ballester and Prof. W. Graham Richards at Oxford (Ballester & Richards, 2007).

Our new approach addressed two Inherent limitations of the network pharmacology approaches available at the time:

Chemical similarity is calculated on the basis of the chemical topology of the small molecule; and
Structural information about the macromolecular target is neglected.

Our method addressed these issues by taking into account 3D information from both the ligand and the target.

The approach involved comparing the similarity of each set ligands known to bind to a protein, to the equivalent sets of ligands of all other known drug targets in DrugBank, DrugBank is a tremendous “bioinformatics and cheminformatics resource that combines detailed drug (i.e. chemical, pharmacological and pharmaceutical) data with comprehensive drug target (i.e. sequence, structure, and pathway) information.” This analysis generated a network of related proteins, connected by the similarity of the sets of ligands known to bind to them.

We looked at two different kinds of ligand similarity metrics, the inverse Manhattan distance of our ElectroShape descriptor, and compared them to 2D Morgan fingerprints, calculated using the wonderful open source cheminformatics toolkit, RDKit from Greg Landrum. Morgan fingerprints use connectivity information similar to that used for the well known ECFP family of fingerprints, which had been used in the SEA method of Keiser et al. We also looked at the problem from the receptor side, comparing the active sites of the proteins. These complementary approaches produced networks that shared a minimal fraction (0.36% to 6.80%) of nodes: while the direct comparison of target ligand-binding sites could give valuable information in order to achieve some kind of target specificity, ligand-based networks may contribute information about unexpected interactions for side-effect prediction and polypharmacological profile optimization.

Our new target-fishing approach was able to predict drug adverse effects, build polypharmacology profiles, and relate targets from two complementary viewpoints:
ligand-based, and target-based networks. We used the DUD and WOMBAT benchmark sets for on-target validation, and the results were directly comparable to those obtained using other state-of-the-art target-fishing approaches. Off-target validation was performed using a limited set of non-annotated secondary targets for already known drugs. Comparison of the predicted adverse effects with data contained in the SIDER 2 database showed good specificity and reasonable selectivity. All of these features were implemented in a user-friendly web interface that: (i) can be queried for both polypharmacology profiles and adverse effects, (ii) links to related targets in ChEMBLdb in the three networks (2D, 4D ligand and 3D receptor), and (iii) displays the 2D structure of already annotated drugs.